Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Br...( -Study Results Show 100-Fold More Ra...),Health

-Study Results Show 100-Fold More Radiation Delivered to Tumor as Compared

to Other Organs- -All Patients Surpassed Expected Median Survival Time at Lowest Planned

Dose Level-

CHICAGO and TUSTIN, Calif., May 31 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical researchers from the Abramson Cancer Center of the University of Pennsylvania will present data showing that its brain cancer agent Cotara(R) specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for glioblastoma multiforme (GBM), a deadly form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. The study results show that the concentration of Cotara in brain tumors was at least 100-fold higher than in other organs, and all of the GBM patients in the study cohort discussed in this presentation have surpassed the expected median six-month survival time for this patient population.

No dose-limiting toxicities were reported in this dosimetry study, confirming other clinical data showing that Cotara appears to have a good safety profile. The Cotara data will be presented on Sunday at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

"These findings confirming Cotara's potential to target its radioactive payload to brain tumors while minimizing radiation exposure to healthy organs have enabled us to advance this Co
'/>"/>